Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: An open-label extension of a randomized, double-blind, placebo-controlled trial

Modern Rheumatology

Volumn 24, Issue 3, 2014, Pages 410-418

  Hara, Masako ^a   Ishiguro, Naoki ^b   Katayama, Kou ^c   Kondo, Masakazu ^d   Sumida, Takayuki ^e   Mimori, Tsuneyo ^f   Soen, Satoshi ^g   Nagai, Kota ^h   Yamaguchi, Tomonobu ⁱ   Yamamoto, Kazuhiko ^j  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Katayama Orthopedic Rheumatology Clinic   (Japan)

^d Kondo Clinic of Rheumatology and Orthopaedic Surgery   (Japan)

^e UNIVERSITY OF TSUKUBA   (Japan)

^f KYOTO UNIVERSITY   (Japan)

^g KINDAI UNIVERSITY NARA HOSPITAL   (Japan)

^h EISAI CO LTD   (Japan)

ⁱ TOYAMA CHEMICAL CO LTD   (Japan)

^j UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

Disease modifying antirheumatic drug; Iguratimod; Methotrexate; Rheumatoid arthritis; T 614

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA 2 MICROGLOBULIN; GAMMA GLUTAMYLTRANSFERASE; IGURATIMOD; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IRON; METHOTREXATE; RHEUMATOID FACTOR; ANTIRHEUMATIC AGENT; CHROMONE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; AMERICAN COLLEGE OF RHEUMATOLOGY CRITERIA; ANAPHYLACTIC SHOCK; ARTICLE; BACKACHE; BACTERIAL PNEUMONIA; BLEEDING TENDENCY; BREAST CANCER; CARBON MONOXIDE INTOXICATION; CONTROLLED STUDY; DAS28; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; ERYTHROCYTE COUNT; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HEMATOLOGIC DISEASE; HUMAN; IRON BLOOD LEVEL; LEUKOCYTE COUNT; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES; MENIERE DISEASE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPEN STUDY; OSTEOMYELITIS; PAROSMIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; STOMACH ULCER; STOMATITIS; SUPRAVENTRICULAR TACHYCARDIA; UPPER RESPIRATORY TRACT INFECTION; UREA BLOOD LEVEL; ARTHRITIS, RHEUMATOID; DRUG COMBINATION; MIDDLE AGED; RETREATMENT; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHROMONES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; RETREATMENT; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84900384454     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.843756     Document Type: Article

References (23)

1. Kawakami A. Tsuboi M. Urayama S. Matsuoka N. Yamasaki S Hida A et al. Inhibitory eff ect of a new anti-rheumatic drug T-614 on costimulatory molecule expression cytokine production and antigen presentation by synovial cells. J. Lab Clin Med. 1999 ; 133(6): 566-74
2. Kohno M. Aikawa Y. Tsubouchi Y. Hashiramoto A. Yamada R Kawahito Y. et al. Inhibitory eff ect of T-614 on tumor necrosis factor-Alpha induced cytokine production and nuclear factorkappaB activation in cultured human synovial cells. J. Rheumatol. 2001; 28(12): 2591-6
3. Aikawa Y. Yamamoto M. Yamamoto T. Morimoto K. Tanaka K. A n anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPSand TNF-Alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Infl amm Res. 2002; 51(4): 188-94
4. Tanaka K. Yamamoto T. Aikawa Y. Kizawa K. Muramoto K Matsuno H et al. Inhibitory eff ects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology 2003 ; 4 2(11): 1 365-7 1
5. Hara M. Abe T. Sugawara S. Mizushima Y. Hoshi K. Irimajiri S et al. Effi cacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: Controlled multicenter double-blind parallel-group study. Mod Rheumatol. 2007; 17(1): 1-9
6. Tian H. Cronstein BN. Understanding the mechanisms of action of methotrexate: Implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007; 65(3): 168-73
7. Chan E S Cronstein B N. Methotrexate-h ow does it really work?. N at Rev Rheumatol. 2010; 6(3): 175-8
8. Akkari R. Burbiel JC. Hockemeyer J. M ü ller CE. Recent progress in the development of adenosine receptor ligands as antiinfl ammatory drugs. Curr Top Med Chem. 2006; 6(13): 1375-99
9. Singh J A Furst D E Bharat A. Curtis J R Kavanaugh A F Kremer J M et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012; 64(5): 625-39
10. Smolen JS. Landew é R. Breedveld FC. Dougados M. Emery P. Gaujoux-Viala C et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010 ; 69(6): 964-75
11. Ishiguro N. Yamamoto K. Katayama K. Kondo M. Sumida T Minori T. et al. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: Randomized double-blind placebo-controlled trial. Mod Rheumatol. 2013; 23(3): 430-9
12. Arnett FC. Edworthy SM. Bloch DA. McShane DJ. Fries JF Cooper NS. et al. The American Rheumatism Association 1987 revised criteria for the classifi cation of rheumatoid arthritis. Arthritis Rheum. 1988; 31(3): 315-24
13. Prevoo M L van t H of M A Kuper H H van Leeuwen M A van De Putte LB. van Riel PL. Modifi ed disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38(1): 44-8
14. Fries JF. Spitz PW. Young DY. The dimensions of health outcomes: The health assessment questionnaire disability and pain scales. J Rheumatol. 1982; 9(5): 789-93
15. Kosinski M. Zhao S Z Dedhiya S. Osterhaus J T Ware J E J r. Determining minimally important changes in generic and diseasespecifi c health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 2000; 43(7): 1478-87
16. Fransen J. van Riel P L. Outcome measures in infl ammatory rheumatic diseases. Arthritis Res Ther. 2009; 11(5): 244
17. Kawai S. Takeuchi T. Yamamoto K. Tanaka Y. Miyasaka N. Effi cacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs-A multicenter double-blind parallel-group trial. Mod Rheumatol. 2011; 21(5): 458-68
18. Tanaka Y. Harigai M. Takeuchi T. Yamanaka H. Ishiguro N. Yamamoto K. et al. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: Results of the GO-FORTH study. Ann Rheum Dis. 2012; 71(6): 817-24
19. Hara M. Abe T. Sugawara S. Mizushima Y. Hoshi K. Irimajiri S. e t a l. Long-Term safety study of iguratimod in patients with rheumatoid arthritis. Mod Rheumatol. 2007; 17(1): 10-6
20. Rheumatoid Arthritis Clinical Trial Archive Group. The eff ect of age and renal function on the effi cacy and toxicity of methotrexate in rheumatoid arthritis. JRheumatol. 1995; 22(2): 218-23
21. Borchers AT. Keen CL. Cheema GS. Gershwin ME. The use of methotrexate in rheumatoid arthritis. Semin Arthritis Rheum. 2004; 34(1): 465-83
22. T ak P P Kalden J R. Advances in rheumatology: New targeted therapeutics. Arthritis Res Ther. 2011; 13 Suppl 1: S5
23. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum. 2002; 46(2): 328-46